![]() | |
Names | |
---|---|
Systematic IUPAC name
tert-Butyl (3S,4S,6R,9S)-13-benzyl-12-hydroxy-6,9-dioxo-7-(propan-2-yl)-10-[(2,3,4-trimethoxyphenyl)methyl]-2-oxa-5,8,14-triazapentadecan-15-oate | |
Identifiers | |
3D model (JSmol) |
|
ChemSpider |
|
PubChem CID |
|
UNII | |
| |
| |
Properties | |
C35H53N3O9 | |
Molar mass | 659.81 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Lasinavir (INN,[1] previously known as BMS-234475 and CGP-61755) is an experimental peptidomimetic protease inhibitor researched by Novartis and Bristol-Myers Squibb as a treatment for HIV infection. It was originally discovered by Novartis at Basel (Switzerland).[2] Its investigation was terminated after Phase I on October 09, 2002.[3]
![]() | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |